The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma

NCT05750797 | Unknown

• 1 other identifier: ESR-21-21329
• Study Type: observational
• Target: 800,000
• Locations: 1 country
• Sites: 1

Brief Summary

The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database.

Conditions

Asthma; Corticosteroid

Outcome Measures

Primary Outcomes (1)

• OCS prescription rates

  Analysis the OCS prescription in all patients with asthma

  1-year

Secondary Outcomes (5)

• OCS prescription according to the asthma severity

  1-year

• OCS prescription according to age

  1-year

• OCS prescription according to sex

  1-year

• OCS prescription according to socioeconomic status

  1-year

• OCS prescription according to the type of hospital

  1-year

Interventions

Oral corticosteroids DRUG

The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Those who were diagnosed and treated as Asthma from 1-Jan-2019 to 31-Dec-2019

You may qualify if:

• Age ≥ 15 years;
• ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis
• use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).

You may not qualify if:

• Those who are not in the insurance system

Sponsors & Collaborators

• Joon Young Choi: lead
• Seoul St. Mary's Hospital: collaborator
• Hallym University Medical Center: collaborator
• Konkuk University Hospital: collaborator

Study Sites (1)

Incheon St. Mary's Hospital

Incheon, Gyeongki, 21431, South Korea

Location

MeSH Terms

Conditions

Asthma

Interventions

Adrenal Cortex Hormones

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Central Study Contacts

Joon Young Choi, MD.PhD

CONTACT

82 10 5313 2937; tawoe@naver.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Clinical assistant professor

Study Record Dates

• First Submitted: February 20, 2023
• First Posted: March 2, 2023
• Study Start: March 1, 2023
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: March 6, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)